Alys Pharmaceuticals
An Innovation Leader in Immuno-Dermatology.
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 94410 % | 49 % | 155 % | 76 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (54515 %) | (1 %) | 15 % | 33 % | 46 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (55361 %) | 3 % | 17 % | 32 % | 40 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 31729 % | 42 % | 24 % | 16 % | 9 % |
Source: Company filings or news article
Related Content
Alys Pharmaceuticals, Inc. is a company focused on immuno dermatology, aiming to redefine the treatment landscape with transformative solutions. The company operates in the pharmaceutical and biotechnology market, specifically targeting dermatological conditions through its innovative programs and platforms. Alys Pharmaceuticals serves patients with dermatological needs, leveraging its robust R&D pipeline enabled by multiple platform technologies. The business model revolves around developing and advancing its pipeline of dermatological treatments, funded by significant investments such as the recent $100 million financing from Medicxi. The company generates revenue through the development and commercialization of its dermatological therapies, potentially partnering with other pharmaceutical companies for distribution and further development.
Keywords: immuno dermatology, R&D pipeline, platform technologies, dermatological treatments, biotechnology, pharmaceutical, innovative programs, Medicxi financing, transformative solutions, dermatological conditions.
